Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Department of Anesthesiology, Xijing Hospital, Air Force Medical University, Xi'an, China.
J Interv Cardiol. 2021 Mar 2;2021:6630774. doi: 10.1155/2021/6630774. eCollection 2021.
The purpose of this study was to review the experiences with transcatheter closure of mitral PVL after surgical valve replacement.
Transcatheter closure of paravalvular leak (PVL) is an intricate alternative to surgical closure. But it represents one of the most intricate procedures in the field of structural heart interventions, especially for patients with mitral PVL.
From January 2015 through January 2019, 35 patients with mitral PVL after valve replacement underwent transcatheter closure. We reviewed the catheter techniques, perioperative characteristics, and prognosis. The median follow-up was 26 (3-48) months.
Acute procedural success was achieved in 33/35 (94.3%) patients. Twenty-five patients had single mitral prosthetic valve replacements; 10 had combined aortic and mitral prosthetic valve replacements previously; 28 had mechanical valves; and 7 had bioprosthetic valves. All percutaneous procedures were performed with local anesthesia except for seven transapical cases with general anesthesia. Multiple approaches were used: transfemoral, transapical, and transseptal via an arteriovenous loop. Multiple devices were deployed. There were no hospital deaths. The procedural time was 67-300 (124 ± 62) minutes. Fluoroscopic time was 17-50 (23.6 ± 12.1) minutes. The hospital stay was 5-17 (8.3 ± 3.2) days. Complications included recurrent hemolysis, residual regurgitation, acute renal insufficiency, and anemia. Twenty-seven (77.1%) patients improved by ≥1 New York Heart Association functional class at the 1-year follow-up.
Transcatheter mitral PVL closure requires complex catheter techniques. However, this minimally invasive treatment could provide reliable outcomes and shorter hospital stays in selected patients. This trial is registered with NCT02917980.
本研究旨在回顾二尖瓣瓣周漏(PVL)经外科瓣膜置换术后行经导管封堵的经验。
经导管封堵瓣周漏(PVL)是外科封堵的一种复杂替代方法。但它是结构性心脏介入领域最复杂的操作之一,尤其是对于二尖瓣 PVL 患者。
2015 年 1 月至 2019 年 1 月,35 例二尖瓣瓣周漏患者在瓣膜置换术后接受了经导管封堵。我们回顾了导管技术、围手术期特点和预后。中位随访时间为 26(3-48)个月。
35 例患者中,33 例(94.3%)即刻手术成功。25 例患者为单瓣机械瓣膜置换;10 例患者先前为主动脉瓣和二尖瓣联合机械瓣膜置换;28 例为机械瓣膜;7 例为生物瓣膜。除了 7 例经心尖入路的病例采用全身麻醉外,所有经皮操作均采用局部麻醉。使用了多种方法:经股动脉、经心尖、经房间隔途径建立动静脉环。使用了多种器械。无院内死亡。手术时间为 67-300(124±62)分钟。透视时间为 17-50(23.6±12.1)分钟。住院时间为 5-17(8.3±3.2)天。并发症包括复发性溶血、残余反流、急性肾功能不全和贫血。27 例(77.1%)患者在 1 年随访时纽约心功能分级至少提高 1 级。
经导管二尖瓣瓣周漏封堵需要复杂的导管技术。然而,这种微创治疗方法可为选定患者提供可靠的结果和较短的住院时间。本试验在 NCT02917980 注册。